Stephan Busque
Stanford University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Stephan Busque as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:59 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07634562 · TLI- and ATG-Enabled Minimization Protocol in Liver TransplantationStanford University · recruiting · Liver Failure · principal investigator
- Ph2NCT06824454 · Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant RecipientsStanford University · recruiting · Hypophosphatemia, Kidney Transplantation · principal investigator
- Ph1NCT05973734 · Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow TherapyStanford University · enrolling by invitation · Islet Transplantation · principal investigator
- Ph1NCT04571203 · Kidney and Hematopoietic Cell Transplants Using a Regimen to Promote Hematopoietic Cell EngraftmentStanford University · recruiting · Immune Tolerance · principal investigator
- Ph1NCT01165762 · Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.Everett Meyer · unknown · ESRD · principal investigator
- Ph4NCT00296296 · Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)Stanford University · completed · Kidney Transplant, Diabetes Mellitus, Type 2, Diabetic Nephropathy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Role of Immune Regulatory Cells in GVHD Prevention and Tolerance InductionP01HL075462 · NHLBI · STANFORD UNIVERSITY · PI Robert S Negrin · fiscal years 2004 to 2020Named on NCT01165762
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:59 UTC. The ranking covers the 200 most relevant of 17 PubMed records, and a shared surname and initials can bring in a namesake. All 17 on PubMed
- Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study.Am J Transplant · 2007164 citationsRCR 4.9
- Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.Am J Transplant · 2012131 citationsRCR 3.7
- Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients.Am J Transplant · 2009111 citationsRCR 2.8
- Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen.Transplant Proc · 200585 citationsRCR 2.9
- Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant.Am J Transplant · 201972 citationsRCR 3.1
- The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation.Am J Transplant · 201169 citationsRCR 2.2
- Experience with the piggyback technique without caval occlusion in adult orthotopic liver transplantation.Transplantation · 199864 citationsRCR 2.7
- Living donor evaluation and exclusion: the Stanford experience.Clin Transplant · 201152 citationsRCR 1.9
- Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients.Transplantation · 200741 citationsRCR 1.6
- Incidental kidney stones: a single center experience with kidney donor selection.Clin Transplant · 201235 citationsRCR 1.5